Iovance Biotherapeutics (IOVA) announced that Raj Puri has been promoted to the newly created role of chief regulatory officer. Puri joined Iovance in March 2022 as executive VP, regulatory strategy and translational medicine.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency
- Iovance Biotherapeutics call volume above normal and directionally bullish
- JMP Securities healthcare analyst holds an analyst/industry conference call
- Iovance Biotherapeutics’ Strong Q3 2024 Performance
- Closing Bell Movers: Toast gains 19% afterhours after earnings beat